[ad_1]
The Russian vaccine against covid-19 is safe, according to the preliminary results of a study published this Friday in the scientific journal The Lancet.
According to the results of the Russian tests, the two candidate variants for a COVID-19 vaccine did not cause serious adverse reactions and elicited an antibody response. The article reports the results of two trials.
The two 42-day trials, which included 38 healthy adults each, “found no serious adverse effects among participants and confirmed that vaccine candidates elicit an antibody response,” according to information released this Friday by the publication.
Large long-term trials, including a comparison with placebo, and additional follow-up are needed to establish the long-term safety and efficacy of the vaccine in preventing the infection that causes COVID-19, emphasizes the text accompanying the dissemination of the results. .
“Two formulations of a two-component vaccine have a good safety profile,” says Lancet, adding that they induced antibodies in all participants within 21 days. The study involves a frozen formulation of the vaccine and a lyophilized one.
The frozen was developed for use on a large scale through existing global vaccine chains, while the lyophilized formula was designed for hard-to-reach regions, as it is more stable and can be stored at 2-8 degrees Fahrenheit, they explain. the scientists.
With these vaccines, adenoviruses are also weakened and cannot replicate in human cells so as not to cause disease. Adenovirus usually causes a common cold.
Explaining why they used two different adenovirus vectors, lead author Denis Logunov from the National Center for Research in Epidemiology and Microbiology at NF Gamaleya, Russia, said: “When adenovirus vaccines enter people’s cells, they provide the genetic code for the SARS-CoV-2 peak protein, which causes cells to produce maximum protein. “
Logunov said this helps teach the immune system to recognize and attack the SARS-CoV-2 virus. “To form a powerful immune response against SARS-CoV-2, it is important that a booster vaccine is provided. However, booster vaccines using the same adenovirus vector may not produce an effective response, because the immune system it can recognize and attack the vector, ”he added.
[ad_2]
